SecBot SecBot
6-K ·Filed Jun 17, 2026

GMAB

GENMAB A/S
NEUTRAL
Impact 2/10
Horizonimmediate Processed5mo ago SEC0001434265-26-000097
Notable filing: 6-K
Actionable Insight • Neutral

This filing is purely administrative with no trading implications. Monitor future 6-K filings for any material business developments such as pipeline updates, partnership changes, or financial results.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$25.39
T+0 close · Jun 17, 2026 · via day close
Latest settled
+27.89%
T+60 · $32.47
Vs SPY
+24.74%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 17 $25.39entry
  2. T+1 · 5mo ago −0.47%α −1.25% · $25.27
  3. T+5 · 5mo ago +1.87%α +2.91% · $25.87
  4. T+20 · 4mo ago +14.14%α +12.82% · $28.98
  5. T+60 · 2mo ago +27.89%α +24.74% · $32.47
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Genmab filed its updated Articles of Association (June 16, 2026) via a 6-K on June 17, 2026. The document is a routine corporate governance update covering standard provisions on share capital, warrant programs, board composition, and meeting procedures. No material financial, operational, or strategic changes were disclosed.

Key Facts

  • Share capital remains DKK 62,353,252 divided into shares of DKK 1 each.
  • Board authorized until March 12, 2029 to increase share capital by up to DKK 6,600,000 with or without pre-emption rights.
  • Multiple warrant programs for employees (excluding executive management) with caps of DKK 750,000 each under various general meeting authorizations.
  • Convertible debt instrument authorization up to DKK 3,000,000 nominal value until March 12, 2029.
  • Indemnification scheme for board members established through March 12, 2029.
  • Group language set to English; annual reports in English (and optionally Danish).

Financial Impact

No financial impact; routine governance filing with no new financial data.

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
76% bullish (25 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001434265-26-000097
Document: gmab_20260617x6k.htm0001434265-26-000097
Document: 0001434265-26-000097-index-headers.html0001434265-26-000097
Document: 0001434265-26-000097-index.html0001434265-26-000097
Document: 0001434265-26-000097.txt0001434265-26-000097

US Market Status

Market Closed · Opens in 9h 1m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 17, 2026